Left ventricular remodelling and dysfunction - Can the process be prevented?

被引:28
作者
Willenheimer, R [1 ]
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Cardiol, S-20502 Malmo, Sweden
关键词
left ventricular remodelling; dysfunction; cardiac failure; process prevention;
D O I
10.1016/S0167-5273(99)00182-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to continuous remodelling myocardial dysfunction is a progressive condition. Even if the initial event is so mild that it causes no immediate cardiac dysfunction (e.g. a small myocardial infarction), the remodelling process is triggered. Although the remodelling process can be adaptive, the process becomes maladaptive when the stimuli are continuous and pathological. A similar remodelling process is seen in most primary myocardial disorders, suggesting common mechanisms for the development of heart failure. Although clinical heart failure may develop acutely, for example, after an acute myocardial infarction, the progressive changes in myocardial structure and deterioration of myocardial function can go on silently fur a very long time and overt heart failure may develop several years after an initial insult, even if then are no further events. In order to fundamentally improve prognosis in cardiac failure it is necessary to identify patients with an ongoing remodelling process and to effectively counteract this process as early as possible. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:143 / 150
页数:8
相关论文
共 69 条
[1]  
Anversa P, 1998, BASIC RES CARDIOL, V93, P8
[2]   ALTERATIONS IN SARCOPLASMIC-RETICULUM GENE-EXPRESSION IN HUMAN HEART-FAILURE - A POSSIBLE MECHANISM FOR ALTERATIONS IN SYSTOLIC AND DIASTOLIC PROPERTIES OF THE FAILING MYOCARDIUM [J].
ARAI, M ;
ALPERT, NR ;
MACLENNAN, DH ;
BARTON, P ;
PERIASAMY, M .
CIRCULATION RESEARCH, 1993, 72 (02) :463-469
[3]  
BALL SG, 1993, LANCET, V342, P821
[4]   Endothelin antagonists [J].
Benigni, A ;
Remuzzi, G .
LANCET, 1999, 353 (9147) :133-138
[5]   INTRACELLULAR CALCIUM HANDLING IN ISOLATED VENTRICULAR MYOCYTES FROM PATIENTS WITH TERMINAL HEART-FAILURE [J].
BEUCKELMANN, DJ ;
NABAUER, M ;
ERDMANN, E .
CIRCULATION, 1992, 85 (03) :1046-1055
[6]  
Brilla C G, 1994, Cardiologia, V39, P389
[7]   Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts [J].
Calderone, A ;
Thaik, CM ;
Takahashi, N ;
Chang, DLF ;
Colucci, WS .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :812-818
[8]   STRETCH-INDUCED PROGRAMMED MYOCYTE CELL-DEATH [J].
CHENG, W ;
LI, BS ;
KAJSTURA, J ;
LI, P ;
WOLIN, MS ;
SONNENBLICK, EH ;
HINTZE, TH ;
OLIVETTI, G ;
ANVERSA, P .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2247-2259
[9]   REGULATION OF HYPERTROPHY AND ATROPHY IN CULTURED ADULT HEART-CELLS [J].
CLARK, WA ;
RUDNICK, SJ ;
LAPRES, JJ ;
ANDERSEN, LC ;
LAPOINTE, MC .
CIRCULATION RESEARCH, 1993, 73 (06) :1163-1176
[10]   A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].
COHN, JN ;
JOHNSON, G ;
ZIESCHE, S ;
COBB, F ;
FRANCIS, G ;
TRISTANI, F ;
SMITH, R ;
DUNKMAN, WB ;
LOEB, H ;
WONG, ML ;
BHAT, G ;
GOLDMAN, S ;
FLETCHER, RD ;
DOHERTY, J ;
HUGHES, CV ;
CARSON, P ;
CINTRON, G ;
SHABETAI, R ;
HAAKENSON, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310